Last week, the CF Foundation sent a letter to President Obama, the Administration's health officials, congressional committees with jurisdiction over health care, and congressional leadership, urging them to recognize the unique health care needs of people with CF as health care reform becomes a priority in Washington.
Site Search
Showing 201 - 210 of 220 results
News
|
April 13, 2009
|
2 min read
News
|
May 28, 2009
|
2 min read
News
|
Jan. 24, 2013
|
5 min read
News
|
Nov. 5, 2013
|
3 min read
News
|
Aug. 31, 2012
|
6 min read
News
|
Oct. 19, 2012
|
3 min read
The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
News
|
July 27, 2012
|
1 min read
News
|
Oct. 23, 2012
|
3 min read
News
|
Oct. 22, 2012
|
2 min read
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.
News
|
March 2, 2012
|
1 min read